Immune-Mediated Hemolytic Anemia
Immune-Mediated Hemolytic Anemia (IMHA) is a life-threatening autoimmune disease where the immune system destroys the body's own red blood cells.
Detailed Description
IMHA is characterized by rapid destruction of red blood cells due to an inappropriate immune response. The condition leads to severe anemia, jaundice, and can be fatal without prompt treatment. The exact cause is often unknown, but genetic predisposition and environmental triggers are suspected.
Common Symptoms
- Lethargy
- Pale gums
- Jaundice
- Dark urine
- Rapid breathing
Management Options
- Immunosuppressive therapy (steroids, other drugs)
- Blood transfusions
- Supportive care
Frequently Asked Questions
Is IMHA curable?
IMHA is not curable, but it can be managed; relapses are possible.
Why are some breeds at higher risk?
Certain breeds have a genetic predisposition to IMHA.
What are the first signs?
Sudden lethargy and pale or yellow gums are common early signs.
Is IMHA contagious?
No, IMHA is not a contagious disease.
How is IMHA treated?
Treatment involves immunosuppressive drugs and supportive care.
Condition Details
📅
Typical Age of Onset
Middle-aged (5–8 years)
📋
Testing Available
No
🔍
Diagnosing Methods
Complete blood count (CBC); Coombs test; Spherocyte identification; Exclusion of other causes
🛡️
Preventative Measures
Early detection and prompt treatment
🔗
Related Conditions
Other causes of anemia (blood loss, non-immune hemolytic anemia)